Navigation Links
Former Fujifilm Medical Systems USA Executive John J. Weber Agrees to Join Regenicin™ as a Member of Its Board of Directors and Interim CFO

NEW YORK, Sept. 13 /PRNewswire-FirstCall/ -- Regenicin™, Inc. (OTC Bulletin Board: WDST), a clinical-stage biotechnology company, announced today that John J. Weber, the former highest ranking American corporate officer at Fujifilm Medical Systems, USA, Inc. ("Fujifilm USA"), has agreed to join the company as a member of Regenicin's board of directors and interim Chief Financial Officer.  Weber brings over 20 years of medical-related corporate, operational and financial management experience to Regenicin.  He will be a driving force in helping to build the corporate structure as well as the sales and distribution platform for the company's future commercialization of PermaDerm™, its proprietary tissue-engineered skin substitute intended to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures.

Weber most recently served as Executive Vice President of Fujifilm USA, the highest ranked American corporate officer, from 2006 until his departure in 2009. His responsibilities included overseeing all corporate activity with the exception of R&D.  During that time Fujifilm was ranked as the fastest growing medical imaging company, consistently ranking #1 or #2 in customer satisfaction.  From 1998 through 2006 he served as Senior Vice President, Operations at Fujifilm USA where he spearheaded the transition of the company from a film distributor to a digital medical informatics company. From 1986 until 1998 he served as CFO where he helped to profitably manage Fuji's growth from an employee base of 75 to over 1,000.  Prior to his distinguished career at Fujifilm USA, Weber served as the CFO for the confectionary and drinks division of Cadbury Schweppes Limited for three years and as Corporate Controller for an additional five years. Weber was a Senior Accountant at Deloitte Haskins and Sells from 1971 until 1975.

Commenting on his decision to join Regenicin, Weber stated, "After almost 25 years of driving the growth of an organization from its infancy in the United States in 1986 and through its evolution into one of the leading medical informatics companies in the United States, I have garnered experience in all aspects of financial and operational management.  I believe Regenicin is at the cusp of a great journey in building a world-class organization with PermaDerm™ products, and I am excited to become a part of it.  I look forward to applying my skills toward building and overseeing the corporate foundation to enable the company to manage the explosive growth potential of this revolutionary technology."

Commenting on the announcement, Randall McCoy, Chief Executive Officer of Regenicin stated, "John brings a wealth of knowledge to our management team and board that will be critical as we build Regenicin into a much larger organization. His hands on experience in structurally and financially managing corporate growth will be key to our company as we set up international and domestic distribution networks and properly manage future growth. We look forward to working with him as we build a top caliber team to manage our company's promising future."

About Regenicin, Inc.

Regenicin™, Inc. is a clinical-stage company developing next-generation tissue-engineered skin substitutes to restore the qualities of healthy human skin. Regenicin is a publicly traded company, with headquarters in New York, NY. Additional information can be found in the company's filings with the Securities and Exchange Commission located at

SOURCE Regenicin, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. UPDATE: Appeal of Lawsuit by Former Chief Executive Officer- Reinstated; and Sanctions Order Vacated
2. Appeal of Lawsuit by Former Chief Executive Officer- Reinstated; and Sanctions Order Vacated
3. Axial Exchange Recruits Karen Evans, Former Fed CIO, to Advisory Board
4. Appeal of Lawsuit by Former Officer Dismissed; Request for Sanctions Granted
5. Former French Prime Minister Jean-Pierre Raffarin Visits Sundia
6. Waukesha Electric partners with SuperPower and UH to build fault current limiting superconducting transformer for Dept. of Energy
7. Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with Best and Brightest Forum on Medical Innovation
8. Frost & Sullivans 2009 Excellence in Healthcare Awards Banquet Honours Industrys Top Performers
9. Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer
10. Exosome Diagnostics Appoints Former Roche Executive Greg Zdechlik as Chief Operating Officer
11. Jesup & Lamont Announces Presenting LifeTech Companies and Former FDA Commissioner at Annual Growth Stock & National Sales Conference
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... the Organization of Black Aerospace Professionals (OPBAP) has been formalized with the signing ... AMA team leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert ...
(Date:11/25/2015)... Oregon , November 25, 2015 ... Market Research Report is a professional and in-depth ... industry.      (Logo: ) ... overview of the industry including definitions, classifications, applications ... is provided for the international markets including development ...
(Date:11/24/2015)... Nov. 24, 2015  Asia-Pacific (APAC) holds the ... (CRO) market. The trend of outsourcing to low-cost ... but higher volume share for the region in ... however, margins in the CRO industry will improve. ... ( ), finds that the market ...
Breaking Biology Technology:
(Date:11/17/2015)... Mass. , Nov. 17, 2015 Pressure ... leader in the development and sale of broadly enabling, ... worldwide life sciences industry, today announced it has received ... its $5 million Private Placement (the "Offering"), increasing the ... $4,025,000.  One or more additional closings are expected in ...
(Date:11/12/2015)... golden retriever that stayed healthy despite having the gene ... new lead for treating this muscle-wasting disorder, report scientists ... and Harvard and the University of São Paolo in ... pinpoints a protective gene that boosts muscle regeneration, ... Children,s lab of Lou Kunkel , PhD, is ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
Breaking Biology News(10 mins):